Nicotine Addiction: What Lights Up the Field - Pharmaceutical Executive

ADVERTISEMENT

Nicotine Addiction: What Lights Up the Field


Pharmaceutical Executive



The market for anti-smoking products exceeds $2 billion, but their superiority over cold-turkey quitting remains controversial. The first vaccines are set to offer a new weapon in the fight against nicotine addiction. Long-lasting single injections, these new vaccines remove the hurdle of daily adherence while sparking the immune system to produce nicotine-specific antibodies that aggregate nicotine in the bloodstream, resulting in a nicotine complex too large to cross the blood-brain barrier where the reward system awaits. Denying the pleasure of the fix may indirectly help minimize the craving that accompanies quitting smoking. Although Nabi Biopharma/GSK's NicVAX is on schedule to beat Novartis' NIC-002 to market, the Swiss firm's vax is expected to grab a larger market share because of its greater efficacy—and Novartis' marketing muscle, says Datamonitor's Ben Greenacre.

ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here